Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia.

Previous studies conducted under basal conditions have suggested a linkage between the formation of plasma triglyceride and the degradation of cholesterol to bile acids. To further examine this relationship, plasma endogenous triglyceride kinetics were determined using [(3)H]glycerol in 26 hyperlipidemic subjects before and during stimulated (cholestyramine treatment) and inhibited (chenodeoxycholic acid treatment) bile acid synthesis. All patients with hyperlipoproteinemia (HLP) type II (n = 9) treated with cholestyramine (12 g daily for 2-4 months) displayed increased apparent biosynthesis (12.8 +/- 1.5 vs. 9.7 +/- 1.2 micro mol kg(-1)hr(-1), mean +/- SEM, P < 0.005) and an elevated apparent fractional turnover rate (0.230 +/- 0.017 vs. 0.176 +/- 0.014 hr(-1), P < 0.001) as determined over a 10-hr period, in spite of essentially unchanged plasma triglyceride concentrations. No consistent effect of this therapy was encountered in the five patients studied with type IV HLP. Chenodeoxycholic acid feeding (1.9 mmol daily for 3-4 months) resulted in a reduced apparent synthesis of plasma triglycerides both in type IIa (n = 5, 7.9 +/- 0.5 vs. 13.1 +/- 1.2 micro mol kg(-1)hr(-1), P < 0.01) and type IV HLP (n = 7, 15.5 +/- 1.8 vs. 23.6 +/- 3.7 micro mol kg(-1)hr(-1), P < 0.02). Furthermore, a 20-25% reduction of the apparent fractional turnover rate was seen, and the plasma concentration of triglycerides was reduced by about 15%. It is concluded that the present experimental conditions that primarily influence cholesterol and bile acid biosynthesis also affect the metabolism of plasma triglycerides-and presumably that of very low density lipoprotein-in a regulatory manner. Hypothetically, this may be achieved via a hepatic pool of newly synthesized cholesterol.

[1]  K. Einarsson,et al.  Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia. , 1978, Journal of lipid research.

[2]  K. Einarsson,et al.  Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size. , 1978, Journal of lipid research.

[3]  K. Einarsson,et al.  Effect of chenodeoxycholic acid on serum and biliary lipids in patients with hyperlipoproteinaemia. , 1978, Clinical science and molecular medicine.

[4]  K. Einarsson,et al.  Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV. , 1977, The Journal of laboratory and clinical medicine.

[5]  S. Grundy,et al.  Changes in plasma triglyceride metabolism during withdrawal of bile. , 1976, Metabolism: clinical and experimental.

[6]  K. Einarsson,et al.  Elimination of cholesterol in hyperlipoproteinaemia. , 1976, Clinical science and molecular medicine.

[7]  M. Kallner The effect of chenodeoxycholic acid feeding on bile acid kinetics and fecal neutral steroid excretion in patients with hyperlipoproteinemia types II and IV. , 1975, The Journal of laboratory and clinical medicine.

[8]  J. Sjövall,et al.  Bile acid metabolism. , 1975, Annual review of biochemistry.

[9]  P. Nestel,et al.  Differences among Hyperlipoproteinaemic Subjects in the Response of Lipoprotein Lipids to Resin Therapy , 1975, European journal of clinical investigation.

[10]  A. Gangl,et al.  Intestinal metabolism of lipids and lipoproteins. , 1975, Gastroenterology.

[11]  K. Einarsson,et al.  Bile acid kinetics in relation to sex, serum lipids, body weights, and gallbladder disease in patients with various types of hyperlipoproteinemia;. , 1974, The Journal of clinical investigation.

[12]  K. Einarsson,et al.  Influence of deoxycholic acid feeding on the elimination of cholesterol in normolipaemic subjects. , 1974, Clinical science and molecular medicine.

[13]  P. Nestel,et al.  Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. , 1974, Lancet.

[14]  K. Einarsson,et al.  Effect of cholic acid feeding on bile acid kinetics and neutral fecal steroid excretion in hyperlipoproteinemia (types II and IV). , 1974, Metabolism: clinical and experimental.

[15]  K. Einarsson,et al.  The Effect of Cholestyramine on the Elimination of Cholesterol as Bile Acids in Patients with Hyperlipoproteinaemia Type II and IV , 1974, European journal of clinical investigation.

[16]  A. Kissebah,et al.  The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia , 1974, European journal of clinical investigation.

[17]  S. Rössner,et al.  Effects of Hypolipidemic Regimes on Serum Lipoproteins , 1974 .

[18]  J. Thistle,et al.  Effect of bile acid feeding on cholesterol metabolism in gallstone patients. , 1974, Mayo Clinic proceedings.

[19]  G. Reaven,et al.  Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. , 1974, The Journal of clinical investigation.

[20]  P. Nestel,et al.  Effects of colestipol, a new bile-acid-sequestering resin, on cholesterol metabolism in man. , 1973, The Journal of laboratory and clinical medicine.

[21]  K. Einarsson,et al.  Feedback regulation of bile acid formation in man. , 1973, Metabolism: Clinical and Experimental.

[22]  J. Thistle,et al.  Effect of oral chenodeoxycholic acid on bile acid kinetics and biliary lipid composition in women with cholelithiasis. , 1973, The Journal of clinical investigation.

[23]  B. Lewis,et al.  Serum Lipids in Cholelithiasis: Effect of Chenodeoxycholic Acid Therapy , 1973, British medical journal.

[24]  K. Einarsson,et al.  The Effect of Clofibrate on the Elimination of Cholesterol as Bile Acids in Patients with Hyperlipoproteinaemia Type II and IV , 1973, European journal of clinical investigation.

[25]  J. Garbutt,et al.  Effect of cholestyramine on bile acid metabolism in normal man. , 1972, The Journal of clinical investigation.

[26]  E. Nikkilä,et al.  Plasma Endogenous Triglyceride Transport in Hypertriglyceridaemia and Effect of a Hypolipidaemic Drug (SU‐13437) , 1972, European journal of clinical investigation.

[27]  E. Nikkilä,et al.  Plasma triglyceride metabolism in thyroid disease. , 1972, The Journal of clinical investigation.

[28]  L. Horlick,et al.  Mechanisms of Action of Cholestyramine in the Treatment of Hypercholesterolemia , 1972, Circulation.

[29]  R. Levy,et al.  Hypolipidemic drugs and lipoprotein metabolism. , 1972, Advances in experimental medicine and biology.

[30]  E. Nikkilä,et al.  Polymorphism of plasma triglyceride kinetics in normal human adult subjects. , 2009, Acta medica Scandinavica.

[31]  S. Grundy,et al.  Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. , 1971, The Journal of laboratory and clinical medicine.

[32]  R. Jones,et al.  Lipoprotein lipid alterations with cholestyramine administration. , 1970, The Journal of laboratory and clinical medicine.

[33]  G R Cooper,et al.  Classification of hyperlipidaemias and hyperlipoproteinaemias. , 1970, Bulletin of the World Health Organization.

[34]  R. B. Moore,et al.  Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient. , 1968, The Journal of clinical investigation.

[35]  O. L. Davies,et al.  Statistical Methods. 6th Edition. , 1968 .

[36]  G. Reaven,et al.  VALIDATION OF AN INCOMPLETELY COUPLED TWO-COMPARTMENT NONRECYCLING CATENARY MODEL FOR TURNOVER OF LIVER AND PLASMA TRIGLYCERIDE IN MAN. , 1965, Journal of lipid research.